Matched sibling BMT is the treatment of choice for many malignant and non-malignant diseases. Unfortunately, donor availability limits its applicability with only approximately one-third of patients having HLAmatched family members. For the remaining two-thirds of patients who need an allogeneic procedure, an alternative donor is required. Matched unrelated donor (MUD) bone marrow transplants have proven useful for many of these patients, however, matched donors may be unavailable or too time-consuming to find. In addition, MUD transplants are associated with high morbidity and mortality secondary to severe graft-versus-host disease (GVHD), organ toxicity, and infections. For those patients without a matched related or unrelated volunteer donor, unrelated umbilical cord blood transplantation (UCBT) is a feasible alternative. UCBT has been associated with a lower incidence and severity of GVHD than MUD BMT, allowing successful transplantation in the HLA-mismatched setting, thus increasing the donor pool. This manuscript reviews the available literature regarding these two procedures, assesses their risk/benefit ratio, and arrives at several conclusions regarding their relative indications. Bone Marrow Transplantation (2000) 25, Suppl. 2, S58-S60.
Although bone marrow transplantation (BMT) has become the standard of care for many diseases, only one-third of patients will have an appropriate family donor, thus limiting its applicability. The development of large volunteer marrow donor registries has allowed finding donors for another 30%. 1 For those patients without a matched unrelated marrow donor (MUD), either an autologous or other alternative allogeneic transplant, such as a mismatched family transCorrespondence: MJ Mogul, Clinical Faculty, Pediatric HematologyOncology/Bone Marrow Transplantation, City of Hope National Medical Center, Coastal Pediatric Hematology/Oncology, PO Box 689, Santa Barbara, CA 93102, USA plant or unrelated umbilical cord blood transplant (UCBT) are the remaining alternatives. Since autologous BMT is not indicated for patients with advanced hematological malignancies or bone marrow failure syndromes, a mismatched BMT or UCBT would be indicated.
Initial reports describing the use of mismatched donor transplants met with limited success secondary to the development of severe graft-versus-host disease (GVHD) and/or graft failure. 2, 3 The introduction of T cell-depletion techniques significantly decreased the risk of GVHD, but this advantage was frequently offset by graft rejection rates approaching 20-30%. 4 Recently, investigators have explored the use of umbilical cord blood stem cells as a rescue source with some exciting results. The first reported successful CBT was in 1988 from a matched related transplant in a patient with Fanconi's anemia. 5 In 1993, investigators at Duke University Medical Center performed the first transplant using an unrelated cord unit facilitated by the New York Blood Center. 6 To date, more than 500 UCBTs have been performed worldwide and approximately 10 000 cord units are cryopreserved in donor banks. By comparison, MUD transplants are performed far more frequently with more than 5700 procedures undertaken, and there are more than 3 million volunteer donors registered worldwide. This manuscript reviews the literature on these two procedures, assesses their risk/benefit ratio, and arrives at several conclusions regarding their relative indications.
Results
A review of the largest published series on UCBT was undertaken and the following data were compared: patient number studied; their eligibility requirements; median age and weight; the median volume of the cord units; the number of total nucleated cells/kg of patient weight infused; the degree of HLA-matching; the time to reach an absolute neutrophil count (ANC) of Ͼ500/mm 3 and the time to reach platelet transfusion independence Ͼ20 000 platelets/mm 3 or Ͼ50 000 platelets/mm 3 , the rate of severe (grade III or IV) GVHD, and the event-free survival at 100 days or longer. [6] [7] [8] [9] [10] The reported data were relatively consistent between sites with the exception of a higher GVHD rate and concomitant poorer survival seen in patients treated in European centers. 9, 10 Overall, more than 500 patients with various malignant (acute leukemia, lymphomas and solid tumors), and nonmalignant disorders (bone marrow failure syndromes, immune deficiency disorders and metabolic/storage diseases) have been transplanted to date. Approximately three-fold more UCBTs have been performed for malignant vs non-malignant disorders, with acute leukemia being the primary indication. The median age was approximately 4.5 years with a range of Ͻ1 month to 58 years. Patient weight ranged from 3.3 kg to Ͼ100 kg. The median volume of cord blood infused was approximately 80 ml with approximately 3.0 ϫ 10 7 total nucleated cells/kg patient weight infused (the ranges were 35-360 ml and 0.7 ϫ 10 7 to Ͼ100 ϫ 10 7 cells/kg, respectively). The majority of cord units were mismatched with their recipients as opposed to the two largest reported series on MUD transplants in children. 11, 12 Time to 500 neutrophils/mm 3 were similar; however, platelet recovery was greatly delayed in the UCBT setting (approximately 70 days vs 23 days to platelet independence at the 50 000 platelets/mm 3 level). GVHD was less common and less severe in the UCBT patients irrespective of the degree of HLAmismatch, a primary factor in their lower regimen-related toxicity as compared to MUD patients, particularly in the HLA-mismatched setting.
Only the patients' disease status (high-risk vs low-risk) was a common prognostic factor in both types of unrelated transplants. Whereas HLA-mismatching was highly prognostic for a poor outcome in MUD patients, this was not the case in UCBT recipients. Of note, the number of nucleated cells/kg patient weight infused appeared to be very important. Kurtzberg et al, 6 as well as Gluckman et al, 9 reported a significant negative impact on survival in patients who received Ͻ3.7 ϫ 10 7 nucleated cells/kg, whereas others believe the lowest acceptable dose to be Ͼ1.0 ϫ 10 7 cells/kg. 13 It has been reported that patient age, CMV status at the time of transplant, as well as the transplant site (American vs European) may impact an UCBT patient's survival. 10 Both Rocha et al 14 and Stiff et al, 15 reporting at the most recent American Society of Hematology meeting, attempted to address the issue of UCBT applicability in the adult patient, for whom cell dose is a primary concern. Rocha et al 14 reported on the Eurocord experience of 42 adult patients with leukemia who received UBCTs. Fourteen patients were considered to have good risk disease (CR1, CR2 or CP1) and 28 to have high-risk (advanced) disease. Their median age was 26 with a median weight of 56 kg. A median total nucleated cell/kg dose of 1.7 ϫ 10 7 cells was infused with a range of 0.2 ϫ 10 7 to 6.0 ϫ 10 7 . Similar to the experience in the pediatric population the majority of the cord units were mismatched at 1 to 3 HLA antigens. When compared to the engraftment seen in the pediatric population, engraftment in this adult population was slightly delayed for neutrophils (median 35 days for adults vs 25 days for children) and significantly delayed for Ͼ20 000/mm 3 platelets (median 176 days in adults vs approximately 55 days for children). Severe GVHD was a significant concern with 13 of 26 (50%) adult patients Bone Marrow Transplantation developing grade III-IV disease. Of the 42 patients, 35 died of regimen-related toxicity, including eight from GVHD which translated into a transplant-related mortality rate of 81%. All patients who received Ͻ1.0 ϫ 10 7 nucleated cells/kg died. Disease status was also prognostic, 36% of the good risk patients were alive at 1 year post transplant as opposed to only 7% of the poor risk patients.
In an attempt to increase the cell dose available from any one unit, Stiff et al, at the same meeting, reported their experience with ex vivo expansion. Nine patients with advanced leukemia were re-infused after myeloablative therapy with a median of 1.15 ϫ 10 7 nucleated cells/kg at day ϩ0 and with the remaining cells expanded ex vivo using a combination of PIXY, Flt3 ligand, and erythropoietin and then re-infused on day ϩ12. The median number of expanded cells infused was 0.6 ϫ 10 7 nucleated cells/kg. All but one patient received mismatched cord cells. WBC engraftment occurred on day ϩ24 but platelet engraftment was unevaluable secondary to the very short follow-up time. Five patients died of a transplant-related complication (56%) and the remaining four patients survive disease-free with 56-292 days of follow-up.
Discussion
UCBT has rapidly become a viable alternative for patients who do not have a matched family donor. When compared to the historic 'gold standard' of alternative donor transplants namely, MUD BMTs, cord units are easier to obtain with no donor risk or attrition. Time to transplantation is far shorter with the average time to obtain a cord unit being 25 days vs 135 days for an unrelated bone marrow (range 1 month to 6 years). 10, 16 The average cost to procure a cord blood unit is less than unrelated marrow, $15 000 compared to $50 000 on average. 8 In addition, cord blood is rarely positive for CMV and EBV (Ͻ1%) when the majority of MUD donors have been exposed to these infectious agents.
One concern with MUD transplants is the relative lack of racial diversity in the donor pool. Cord blood, on the other hand, can be easily collected without risk from any targeted racial group. In addition, since it does not appear that an HLA-matched unit is necessary for successful engraftment without life-threatening GHVD also increases the possibility that an acceptable cord unit can be found for virtually all patients. Whereas, 47% of MUD transplant patients develop grade III-IV GVHD almost all of whom succumb to this complication, severe GVHD is rare (Ͻ20%) even with a 2 or 3 HLA antigen mismatched UCBT with very few deaths attributable to GVHD. In the paper by Gluckman et al 17 20% of patients developed severe GVHD but fortunately only 6% died of this complication. Conversely, in the paper published by Kurtzberg et al, 6 no patient suffered grade IV disease and no patient died of GVHD.
One possible explanation for this phenomenon was reported by Risdon et al, 18 who found that umbilical cord blood cells are 10-1000 times less alloreactive than adult peripheral blood cells. The same group has also reported that umbilical cord cells have increased CD8
ϩ suppressor cell activity which in turn, induces a state of anergy to allo-reactivity. 19 Whether the decreased GVHD associated with UCBT causes less of a GVL effect is yet to be determined, but preliminarily this does not appear to be the case.
Even though cord units may be available for virtually any patient, clearly the size of the patient remains a significant concern. Cell dose appears to be an important prognostic factor for survival in the UCBT setting. 6, 9, 10 Perhaps additional research in the exciting field of ex vivo cord blood stem cell expansion will obviate this concern in the future. Other concerns regarding the increased use of UCBTs are the small yet real risk of transmitting an unknown genetic disorder such as SCID, thalassemia, infantile ALL, Fanconi's anemia, and others. Delayed engraftment continues to be a problem particularly for platelets. Preliminary experience suggests that patients with bone marrow failure syndromes may be a particular risk of non-engraftment. 9 Whether growth factors are of benefit in engraftment is unclear. The same investigators have reported both their usefulness and lack of same. 7, 20 The use of donor leukocyte infusions either as postrelapse therapy or as prophylaxis against relapse has shown significant promise. Another disadvantage of UCBT is that the investigator cannot go back and get more donor cells to treat either graft rejection, or for subsequent donor leukocyte infusion.
Lastly, there are ethical concerns related to UCBT that have yet to be satisfactorily addressed. Several for-profit companies are attempting to obtain cord units from families for 'safe-keeping' at significant financial cost and with questionable future benefit. It is also not clear who 'owns' the unit once the donor reaches the age of maturity. Conflict could arise should the donor's parents wish to use the unit for an allogeneic procedure against the donor's wishes.
In summary, UCBT is clearly a procedure that can benefit many patients for whom there may be little alternative. In addition, cord blood is available almost immediately which would make this form of transplant the treatment of choice for patients who cannot afford the luxury of waiting for a MUD donor secondary to the risk of death from disease progression in the interim. Conversely, patients who are expected to be stable for the 3 to 5 month period required to obtain a MUD BMT, a cord unit is an excellent alternative should an appropriately HLA-matched marrow donor not be available within a specified period of time. Lastly, given the very high transplant-related mortality of a mismatched unrelated bone marrow transplant, an UCBT (even highly mismatched) should be performed preferentially, providing a unit of reasonable size can be obtained.
